España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Vertex Pharmaceuticals
VRTX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$462.10
2.18
0.47%
At close: -
$462.10
0.00
0.00%
After Hours: 4:34 PM EDT
Get Report
Comment
Vertex Pharmaceuticals (VRTX) Forecast
News
Earnings
Vertex Pharmaceuticals (VRTX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
Vertex Pharmaceuticals Stock (NASDAQ: VRTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 04, 2024
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Vandana Singh
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Monday, November 25, 2024
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Benzinga Insights
Monday, November 18, 2024
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Benzinga Insights
Friday, November 15, 2024
Shares of pharmaceutical companies are tradin...
Benzinga Newsdesk
Thursday, November 14, 2024
InspiroGene by McKesson Partners With Vertex ...
Benzinga Newsdesk
Citigroup Initiates Coverage On Vertex Pharma...
Benzinga Newsdesk
Wednesday, November 06, 2024
Canaccord Genuity Maintains Sell on Vertex Ph...
Benzinga Newsdesk
Tuesday, November 05, 2024
Scotiabank Maintains Sector Perform on Vertex...
Benzinga Newsdesk
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Benzinga Insights
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
Piero Cingari
UBS Maintains Buy on Vertex Pharmaceuticals, ...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Ve...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Vertex Phar...
Benzinga Newsdesk
Vertex Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Benzinga Insights
Morgan Stanley Maintains Equal-Weight on Vert...
Benzinga Newsdesk
Monday, November 04, 2024
Vertex Pharmaceuticals Sees FY 2024 Product R...
Benzinga Newsdesk
Vertex Pharmaceuticals Q3 2024 Adj EPS $4.38 ...
Benzinga Newsdesk
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
Piero Cingari
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
Surbhi Jain
Thursday, October 31, 2024
Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
Avi Kapoor
Wednesday, October 30, 2024
Oppenheimer Maintains Outperform on Vertex Ph...
Benzinga Newsdesk
Monday, October 28, 2024
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Benzinga Insights
These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
Chris Katje
Friday, October 25, 2024
Vertex Provides Updates On Multiple Kidney Pr...
Benzinga Newsdesk
Monday, October 21, 2024
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Vertex ...
Benzinga Newsdesk
Friday, October 18, 2024
Market Whales and Their Recent Bets on VRTX Options
Benzinga Insights
Vertex To Present Phase 3 Data Highlighting S...
Benzinga Newsdesk
Thursday, October 17, 2024
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
Benzinga Insights
UBS Maintains Buy on Vertex Pharmaceuticals, ...
Benzinga Newsdesk
Wednesday, October 16, 2024
Scotiabank Initiates Coverage On Vertex Pharm...
Benzinga Newsdesk
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Benzinga Insights
Tuesday, October 15, 2024
Check Out What Whales Are Doing With VRTX
Benzinga Insights
Monday, October 14, 2024
B of A Securities Maintains Buy on Vertex Pha...
Benzinga Newsdesk
Thursday, October 10, 2024
Raymond James Reinstates Market Perform on Ve...
Benzinga Newsdesk
Wednesday, October 09, 2024
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Vandana Singh
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk
Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta
Benzinga Neuro
Tuesday, October 08, 2024
Cantor Fitzgerald Reiterates Overweight on Ve...
Benzinga Newsdesk
Monday, October 07, 2024
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Piero Cingari
Friday, October 04, 2024
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk
Tuesday, October 01, 2024
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Benzinga Insights
Morgan Stanley Maintains Equal-Weight on Vert...
Benzinga Newsdesk
Thursday, September 26, 2024
Vertex Announces Health Canada Acceptance Of ...
Benzinga Newsdesk
Wednesday, September 25, 2024
Health Canada Approves CASGEVY (Exagamglogene...
Benzinga Newsdesk
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Benzinga Insights
Thursday, September 19, 2024
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch